Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 10/20 | 0.55 |
| ▸ | HPN | P05981 | 3/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.49 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | PROC | P04070 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309168 | 0.90 | PLG (0.67) | PLGHPNF10F2ST14 | |
| SCHEMBL29692642 | 0.90 | PLG (0.67) | PLGHPNF10F2ST14 | |
| SCHEMBL1330017 | 0.89 | PLG (0.59) | PLGHPNF10F2ST14 | |
| SCHEMBL1330019 | 0.89 | PLG (0.59) | PLGHPNF10F2ST14 | |
| SCHEMBL29692554 | 0.89 | PLG (0.59) | PLGHPNF10F2ST14 | |
| SCHEMBL20560096 | 0.87 | PLG (0.57) | PLGHPNF10ST14HGFAC | |
| SCHEMBL1328461 | 0.87 | PLG (0.57) | PLGHPNF10ST14HGFAC | |
| SCHEMBL18811787 | 0.86 | PLG (0.50) | PLGHPNF10F2ST14 | |
| SCHEMBL12125514 | 0.85 | PLG (0.56) | PLGHPNF10F2ST14 | |
| SCHEMBL1460406 | 0.83 | F2 (0.56) | PLGHPNF10F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | PLG 443/4885HPN 197/4885F10 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.